BioLargo's Subsidiary Clyra Medical Adds Third Distribution Channel Accelerating Commercial Rollout of ViaClyr Wound Irrigation SolutionAgreement with Spartan Medical opens adds a channel to the U.S. government healthcare market, supplementing existing U.S. commercial distribution and 18 foreign countries.
BioLargo to Participate in Gabelli Funds' 4th Annual PFAS Symposium in New YorkFormer U.S. EPA senior executive Sally Gutierrez will represent BioLargo at the investor event.
BioLargo Reports Second Quarter 2026 Results; Revenue Up 12% Sequentially, Gross Margin Expands to 54%Consumer Products Relaunch Set for October Under a Company-Owned Model; Clyra Medical Scaling Ahead of a Second Product Launch; Company to Host Stockholder Town Hall on September 10, 2026
BioLargo Joins New Jersey Institute of Technology-Led PFAS Consortium; President Tonya Chandler Appointed to Board of DirectorsCompany to contribute commercial PFAS treatment expertise alongside leading universities, regulators, utilities, and industry organizations advancing next-generation PFAS solutions.
BioLargo Equipment Solutions & Technologies' "PFAS Lady" to Teach PFAS 101 at 41st Annual Tri-State SeminarTonya Chandler will lead a seven-hour continuing education course for the fourth consecutive year at one of the water industry's largest regional gatherings
BioLargo PFAS Treatment Technology Featured in The Disruptive QuarterlyCompany leaders join environmental attorneys, academic researchers, and industry innovators in a special issue on forever chemicals and the protection of clean water
BioLargo Relaunching CupriDyne(R)-Based Consumer Products - Back by Popular Demand and Generated More than $125 Million in Pet-Care SalesBioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne® technology under its own brand following the marketing success of the original Pooph products that generated more than $125 million in pet-care sales while under license from BioLargo.
